USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Improved Accuracy for Localization of Radiotherapy Treatment to Drive the Demand for Fiducial Markers
29-May-2019
North America
Market Research
9AB9-00-A8-00-00
HC03177-NA-MR_23232
15 to 20 million new cases of cancer are diagnosed every year. Radiotherapy is the gold standard for treatment and is used on more than 3.5 million people and provided as palliative or adjunct treatment for an additional 3.5 million people, worldwide. Nearly 50 percent of all cancer patients are estimated to benefit from radiotherapy for disease management. Radiotherapy is used in cancers that are localized; it can provide excellent control with no recurrence in the treated area. Radiotherapy is also frequently used in combination with surgery or with chemotherapy.
As radiotherapy is a more cost-effective cancer treatment modality, expanding the services of radiotherapy is necessary to providing effective treatment strategies for cancer across care settings. Delivery of radiotherapy with high accuracy and precision—to reduce injury to normal tissues—is the need of the hour. Fiducial markers enable providers to accurately locate tumor lesions and deliver localized and targeted radiotherapy with higher accuracy. Implantation of gold fiducial markers is a cost-effective method. Complications from fiducial marker implantation are not common. Migration of implanted markers is rare and clinically insignificant. Fiducial markers are now considered the standard of care in the delivery of modern prostate RT, and their use is recommended, especially at dose escalation. Fiducials are an excellent surrogate for prostate position and allow for accurate treatment delivery and minimize the effect of radiation on surrounding organs. The main purpose of using fiducial markers is to increase treatment precision where tracking a tumor is difficult. Fiducial markers are commonly used in prostate and lung cancer and are still in the early stages of being used in the treatment of breast, liver and pancreatic cancer.
Lack of clarity on reimbursement, patient selection, lack of training and skill set, and adoption of CBCT are the main challenges to widespread adoption of fiducial markers. On the other hand, easy implantation, low cost, potential for use in future diagnostic purpose, and well-established clinical evidence serve as major driving factors. The research service provides an end-user and market perspective for the use of fiducial markers in US and Europe and provides a five-year forecast from 2017 to 2022. The unique value of this study is that it provides insights gathered from more than 150 end users, including oncologists, interventional radiologists, radiation oncologists, urologists, and pulmonologists. The key applications covered in the report include breast cancer, liver cancer, prostate cancer, lung cancer, and pancreatic cancer. In depth analysis is provided for prostate and lung cancer.
Author: Sowmya Rajagopalan
Executive Summary—Fiducial Markers Market in the United States and Europe
US and European Fiducial Markers Market Summary
Research Scope and Segmentation
US and EU Fiducial Markers Market—Cancer Type Snapshot
EU and US Fiducial Markers Market—Summary
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
Revenue Forecast
US Fiducial Markers Market Explained
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors for not Using Fiducial Markers—Lung Cancer
Key Factors for not Using Fiducial Markers—Prostate Cancer
Key Challenges with Existing Fiducial Markers—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Key Criteria for Ideal Fiducial Marker—Lung Cancer
Key Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Buying Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Procedural Infrastructure, Prevalence, and Incidence
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
German Fiducial Markers Market Snapshot
German Fiducial Markers Market Explainedncrease.
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
French Fiducial Markers Market Snapshot
French Fiducial Markers Market Explained
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
UK Fiducial Markers Market Snapshot
UK Fiducial Markers Market Explained
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
Italian Fiducial Markers Market Snapshot
Italian Fiducial Markers Market Explained
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
Spanish Fiducial Markers Market Snapshot
Spanish Fiducial Markers Market Explained
Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (Continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Overview
Infrastructure, Prevalence, and Incidence Statistics
Procedural Volume Breakdown
Utilization of Radiotherapy in Cancer Treatment
Swiss Fiducial Markers Market Snapshot
Swiss Fiducial Markers Market Explained
Swiss Fiducial Markers Market Share Analysis
Procedure Cost and Reimbursement
Cancer Treatment Procedural Volume by Practice Size
Budget Allocation and Radiotherapy Procedural Volume
Annual Budget Allocation and Spending on Fiducial Markers
Introduction of Fiducial Markers to Professionals
Services that Professionals Require of Manufacturers
Patient Indication for Using Fiducials in Prostate and Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer
Fiducial Marker Usage in the Treatment of Lung Cancer (continued)
Fiducial Marker Usage in the Treatment of Prostrate Cancer
Fiducial Marker Usage in the Treatment of Prostrate Cancer (continued)
Placement of Fiducial Markers
Ideal Fiducial Marker Cost and Patient Adoption
Key Factors that Affect Use of Fiducials—Lung Cancer
Key Factors that Affect Use of Fiducials—Prostate Cancer
Key Challenges with Existing Fiducials—Lung Cancer
Key Challenges with Existing Fiducials—Prostate Cancer
Important Criteria for Ideal Fiducial Marker—Lung Cancer
Important Criteria for Ideal Fiducial Marker—Prostate Cancer
Fiducial Marker Type Preferences for Prostate and Lung Cancer
End-user Perspective—Liquid Markers
End-user Perspective—CBCT
Endoscopy Approach and Use of Fiducials in MI Surgery
Image Guidance in the Treatment of Cancer
Key Brand Selection Criteria
Impact of Fiducial Marker Adoption—Applications and Potential Use
Growth Opportunities Critical for Future Strategy
Growth Opportunities Critical for Future Strategy (continued)
Strategic Imperatives for Success and Growth
3 Big Predictions
Legal Disclaimer
List of Exhibits
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Brahadeesh Chandrasekaran |
| Industries | Healthcare |
| WIP Number | 9AB9-00-A8-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9A47-B1,9A48-B1,9A4B-B1,9837-B1 |